n-(2-methoxybenzyl)-n-(4-phenoxypyridin-3-yl)acetamide has been researched along with Psychotic-Disorders* in 2 studies
2 other study(ies) available for n-(2-methoxybenzyl)-n-(4-phenoxypyridin-3-yl)acetamide and Psychotic-Disorders
| Article | Year |
|---|---|
Brain TSPO imaging and gray matter volume in schizophrenia patients and in people at ultra high risk of psychosis: An [
Patients with schizophrenia show whole brain and cortical gray matter (GM) volume reductions which are progressive early in their illness. Microglia, the resident immune cells in the CNS, phagocytose neurons and synapses. Some post mortem and in vivo studies in schizophrenia show evidence for elevated microglial activation compared to matched controls. However, it is currently unclear how these results relate to changes in cortical structure.. Fourteen patients with schizophrenia and 14 ultra high risk for psychosis (UHR) subjects alongside two groups of age and genotype matched healthy controls received [. These findings suggest that microglial activity is related to the altered cortical volume seen in schizophrenia. Longitudinal investigations are required to determine whether microglial activation leads to cortical gray matter loss. Topics: Acetamides; Adolescent; Adult; Brain; Carbon Radioisotopes; Female; Gray Matter; Humans; Magnetic Resonance Imaging; Male; Positron-Emission Tomography; Psychotic Disorders; Pyridines; Receptors, GABA; Schizophrenia; Young Adult | 2018 |
Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [
Several lines of evidence are indicative of a role for immune activation in the pathophysiology of schizophrenia. Nevertheless, studies using positron emission tomography (PET) and radioligands for the translocator protein (TSPO), a marker for glial activation, have yielded inconsistent results. Whereas early studies using a radioligand with low signal-to-noise in small samples showed increases in patients, more recent studies with improved methodology have shown no differences or trend-level decreases. Importantly, all patients investigated thus far have been on antipsychotic medication, and as these compounds may dampen immune cell activity, this factor limits the conclusions that can be drawn. Here, we examined 16 drug-naive, first-episode psychosis patients and 16 healthy controls using PET and the TSPO radioligand [ Topics: Acetamides; Adult; Biomarkers; Brain; Carbon Radioisotopes; Case-Control Studies; Female; Gray Matter; Humans; Male; Microglia; Neuroglia; Positron-Emission Tomography; Psychotic Disorders; Pyridines; Radioligand Assay; Radiopharmaceuticals; Receptors, GABA; Schizophrenia | 2017 |